Display options
Cite
Hu C, Yu M, Ren Y, et al. Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep. 2017;7(1):15260doi: 10.1038/s41598-017-14858-z.
Hu, C., Yu, M., Ren, Y., Li, K., Maggio, D. M., Mei, C., Ye, L., Wei, J., Jin, J., Zhuang, Z., & Tong, H. (2017). Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Scientific reports, 7(1), 15260. https://doi.org/10.1038/s41598-017-14858-z
Hu, Chao, et al. "Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation." Scientific reports vol. 7,1 (2017): 15260. doi: https://doi.org/10.1038/s41598-017-14858-z
Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H. Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Sci Rep. 2017 Nov 07;7(1):15260. doi: 10.1038/s41598-017-14858-z. PMID: 29116110; PMCID: PMC5677121.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2017 Nov 07;7(1):15260. doi: 10.1038/s41598-017-14858-z.

Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.

Scientific reports

Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, Hongyan Tong

Affiliations

  1. Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People's Republic of China.
  2. Department of Hematology, Hangzhou First People's Hospital, Hangzhou, 310006, Zhejiang Province, People's Republic of China.
  3. Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People's Republic of China.
  4. Department of Hematology, Yin Zhou People's Hospital, Ningbo, 315040, Zhejiang Province, People's Republic of China.
  5. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA.
  6. Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA. [email protected].
  7. Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People's Republic of China. [email protected].
  8. Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People's Republic of China. [email protected].

PMID: 29116110 PMCID: PMC5677121 DOI: 10.1038/s41598-017-14858-z

Abstract

A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.

Publication Types